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SUMMARY 
 
Myxomatous Mitral Valve Disease is a degenerative condition of the mitral valves leaflets. A 10-year-old 
male castrated Shih Tzu was presented with primary complaint of coughing. Clinical examination revealed normal 
heart rate, respiratory rate and rectal temperature. Systolic murmur Grade IV/VI was heard at the left heart apex. 
Thoracic radiographic findings were cardiomegaly with the vertebral heart score of 11.0 and had evidence of 
cardiogenic pulmonary edema. Echocardiographic examination revealed thickening mitral valves with evidence of 
moderate regurgitation observed. Based on the findings obtained, the dog was diagnosed with Myxomatous Mitral 
Valve disease stage C2. Dog was treated with benazepril (0.5mg/kg), pimobendan (0.2mg/kg) with a combination of 
furosemide (2mg/kg). Frusemide was gradually removed from the treatment regime as coughing improved over time. 
The dog was no longer lethargy and even gained weight.  
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INTRODUCTION 
 
Cardiovascular system comprises of the heart, veins 
and arteries. Atrioventricular (mitral and tricuspid) valves 
and semilunar (aortic and pulmonic) valves keep blood 
flowing in one direction (Borde et al., 2018). In left 
ventricle, the inlet valve is known as the mitral valve 
while the outlet valve is aortic valve. As for right 
ventricle, the inlet valve will be tricuspid valve while the 
outlet valve is pulmonic valve.  
Chronic degenerative valvular disease is 
characterised by the thickening the atrioventricular valves. 
Myxomatous degeneration of the mitral refers to 
thickening of mitral valves due to degeneration that leads 
to failure of the leaflets to close completely and resultant 
in turbulent flow during systole. Myxomatous mitral valve 
disease (MMVD) is most common heart disease (70%) in 
small breed dogs (Detweiler & Paterson, 1965 and 
Borgarelli et al., 2008).  
Insufficiency of the thicken mitral valves to close 
completely would contribute to regurgitation of the blood 
flow that can further be described as mild, moderate and 
severe. The sound produced by the turbulence of the 
blood flow called as cardiac murmur can be heard upon 
auscultation. In mitral regurgitation, systolic murmur can 
be auscultated, louder especially at the left apical of the 
heart. The intensity of the murmur can be associated to the 
severity of the cardiac diseases. Relativity, dogs that have 
louder murmur would have a higher left atrium to aortic 
ratio, which signifies a more severe cardiac disease 
(Haggstrom et. al., 1995). 
Previous report by Teoh and Khor (2017) noted the 
benefits of pimobendan in improving quality of life in 
patient diagnosed with MMVD stage D that were treated 
as outpatient. This case reports outline the benefits of 
pimobendan therapy in a dog diagnosed with MMVD 
stage C2. 
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CASE REPORT 
 
History and Physical Examination 
 
A 10-year-old castrated male Shih Tzu dog was 
presented with a one month history of lethargic, coughing 
and exercise intolerance. Dog was hyporexia and 
observed to be duller during the one month period 
according to owner. Clinical presentation revealed normal 
rectal temperature (38.5°C), normal heart rate of 120 beats 
per minute and normal respiratory rate of 48 breaths per 
minute. Upon auscultation, a cardiac murmur Grade IV/VI 
was auscultated with the maximum point of intensity 
(PMI) at the left heart apex. Results of the complete blood 
count and serum biochemistry blood test were 
unremarkable.  
 
Thoracic Radiography and Echocardiography 
 
Two views thoracic radiograph were obtained 
(Figure 1). Right lateral thoracic radiograph findings 
revealed a cardiomegaly with a vertebral heart score 
(VHS) of 11.0 and an elevated trachea dorsally. There was 
bulge at 10 to 12 clock face; suggestive of right atrium 
enlargement. Besides that, there was an increased 
radiopacity noted at perihilar and cranial lung field with 
alveolar pattern suggestive of cardiogenic pulmonary 
edema. On the dorsalventral view of the thoracic 
radiograph, the evidence of pulmonary edema was more 
prominent on the left caudal of the lung. The cardiac 
outline of the left border of the heart was not very clear 
and the pulmonary veins on the left appeared more 
distended. 
Echocardiography performed revealed that the 
anterior and posterior leaflets of the mitral valves are 
thickened (Figure 2) and mitral valve regurgitation was 
noted to be moderate. Other echocardiographic 
measurements were tabulated in Table 1. The final 
diagnosis was myxomatous mitral valve disease stage C2.  
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Figure 1. Thoracic radiograph at right lateral view, revealing elevated trachea, vertebral heart score of 11.0 and 
pulmonary edema at perihilar region. Thoracic radiograph at dorsoventral view, pulmonary edema can be seen 
at the left lung field.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Echocardiography - Right parasternal 
long axis view. Both anterior and posterior leaflet of 
mitral valves are thickened.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Echocardiography- Right parasternal 
long axis view. Moderate regurgitation was noted 
using the Dopper continuous wave.  
 
 
Table 1. Echocardiographic measurements taken with reference to the M-mode image of the right parasternal 
short axis view.  
 
 
 
LVIDd, LVIDs = left ventricular internal dimension at end-
diastole and end-systole; IVSd, IVSs = interventricular septal 
wall thickness at end-diastole and end-systole; LVPWd, 
LVPWs = left ventricular posterior wall thickness at end-
diastole and end-systole; La = left atrial dimension; Ao = 
aortic root dimension; %EF = percentage ejection fraction; 
%FS = percentage fractional shortening 
 
Variable Mean (cm) Variable Mean 
IVSd 6.90 
 LVIDd 19.50 
LVPWd 6.10 
IVSs 8.60 La:Ao ratio 1.50 
LVIDs 13.2 % EF 64 
LvPWs 9.10 %FS 32 
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Treatment and Progression 
 
Dog was medicated with benazepril hydrochloride 
0.5 mg/kg orally once a day (Fortekor 5 mg, Novartis, 
Canada) as a vasodilator for the treatment of MMVD. For 
pulmonary edema, a loop diuretic of furosemide 2 mg/kg 
(Rasitol 40 mg, Y.S.P. Industries (M) Sdn. Bhd., 
Malaysia) was given two times a day for 7 days, then once 
for 14 days, lastly followed by every other day for 7 days. 
However, the episodes of coughing did not resolve 
completely with the combination of the therapy, 
furosemide cannot be weaned off during the long term 
treatment period of 150 days in total. 
An inodilator, a divided dose of pimobendan 0.5 
mg/kg (Vetmedin® Chew 5 mg, Boehringer Ingelheim, 
Germany) was then advised and started on day-151 post-
treatment of MMVC Stage C2. Benazepril and frusemide 
was maintained at the same dosage and interval for two 
weeks. Besides that, Hijuven (Tocopheryl nicotinate 1 
capsule, Eisai (M) Sdn Bhd, Malaysia) was added as anti 
oxidant. Serratiopeptidase 1 tablet (Pepzen, Prime 
Pharmacy (M) Sdn Bhd, Malaysia) was given as anti-
inflammatory while bromhexine hydrochloride 1 mg/kg 
(Bislan 8 mg, Y. S. P. Industries (M) Sdn Bhd, Malaysia) 
as mucolytic agents. Within 2 weeks of the treatment, the 
dog’s condition improved with medications and episodes 
of cough was no longer heard after one week of the 
treatment. A thoracic radiography was taken on day-165. 
Findings revealed that there were improvement of the 
cardiogenic pulmonary edema and the vertebral heart 
score reduced to 9.0 post treatments (Figure 3). All the 
other medications were stopped and patient was only 
maintained with benazepril hydrochloride and 
pimobendan orally daily. To date after 180 days on the 
two dugs combination, the dog did not have any episodes 
of coughing and very active.  
As for nutritional support and wellness of the heart 
condition, dog was maintained on Cardiac Diet (Royal 
Canine®, France) since the first day of treatment.  
 
Figure 3. Thoracic radiograph post treatment, 
pulmonary edema improved and vertebral heart score 
of 9.0. 
 
 
DISCUSSION 
 
Atrioventricular valvular heart diseases are the most 
common heart disease (70%) in small breed dogs 
(Borgarelli et al., 2008, Detweiler& Paterson, 1965). 
Mitral valves have been reported to be more susceptible 
than tricuspid valve to succumb to myxomatous 
degeneration resulting in myxomatous mitral valve 
degeneration (Disaltian, 2010). Approximately 30% of 
asymptomatic MMVD will have a progression heart 
failure and eventually death as consequences of the 
disease (Borgarelli & Haggstorm, 2010).  
MMVD is mostly diagnosed in small breed dogs, 
predominantly the Cavalier King Charles Spaniel, 
ShihTzu, Poodles, Chihuahua, Pekingnese and 
Dobermann (Borgarelli & Haggstorm, 2010; Borgarelli et 
al.,2012; Borgarelli & Buchanan 2012). Males are more 
often presented than female (Borgarelli & Haggstorm, 
2010; Borgarelli et al.,2012), and there is a strong 
correlation between the body weight and MMVD (Parker  
et al., 2012). In this case, the patient was a male Shih Tzu. 
The common presenting clinical signs of canine 
cardiac patients will be coughing (75%), syncope (49%), 
and cyanosis (14%) (Kim et al., 2017). However, in the 
present case, the patient’s condition was not severe. Only 
coughing, lethargy and hyporexia was observed. Dogs 
with MMVD are normally presented with systolic murmur 
which is best heard at the left cardiac apex and there is a 
strong correlation between the cardiac murmur and 
severity of MMVD (Disaltian, 2010).  
Canine patients that have larger VHS of more than 
10.5 had two times higher possibility of death compared 
to those that had VHS of less than 10.5 (Kim et al., 2017). 
Presence of cardiogenic pulmonary edema, larger 
vertebral heart score and dyspnea are associated with 
shorter survival time (Kim et al., 2017). As the cardiac 
disease progresses over time, the size of the left atrium 
will be larger, causing more clinical signs and reflecting a 
more severe cardiac disease. The patient in this case had a 
VHS of 11.0 and with evidence of pulmonary edema. 
In any cardiac disease patient, echocardiography 
provides a definitive real-time diagnosis of the heart 
condition. Echocardiography evaluate the structure of the 
heart as well as provides more measurement details 
regarding the degree of right or left atria enlargement, end 
diastolic volume, ejection fraction and fractional 
shortening. The common echocardiographic findings of 
MMVD will be thickening or one or both mitral valves 
according to ACVIM consensus (adapted from the 
American College of Cardiology/American Heart 
Association classification system). A higher left atrium to 
aortic ratio is also associated with a more severe 
atrioventricular valvular heart disease (Borgarelli et 
al.,2012). Additionally, age, left atrial to aortic ratio, 
ejection fraction and left ventricular end diastolic volume 
had been associated with a higher risk of death (Kim et 
al., 2017).  
The ACVIM classification (Table 1) of cardiac 
disease uses an A through D categorization of cardiac 
disease and does not rely heavily upon exercise tolerance 
as a criterion, a weakness of previous schemes. It also 
includes a category (A) for dogs without heart disease but 
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who are at risk (e.g., Cavalier King Charles Spaniels at 
risk to develop MMVD). Category B identifies dogs with 
mild heart disease, without (B1) and with (B2) 
cardiomegaly, but without present or historical evidence 
of CHF. Category C identifies dogs with signs of heart 
failure, either hospitalized (C1) or treated at home (C2) 
and is similar to category D, which includes refractory or 
end-stage heart failure patients, treated in the hospital 
(D1) or at home (D2) (Atkins et al., 2009). As in this case, 
the patient can be categorised into Category C2, which are 
dogs with signs of heart failure; including lethargy, 
coughing. The medications recommended by ACVIM 
consensus for patient stage C2 will be furosemide at 1-
4mg/kg, dose can be adjusted as needed depending on the 
condition; pimobendan 0.2-0.3 mg/kg twice daily; and 
angiotensin-converting enzyme inhibitor (ACE-i) 0.5 
mg/kg in MMVD dogs. Treatment should be 
individualised to minimise the clinical signs and improve 
quality of life (Borgarelli & Buchanan 2012).  
 
Table 1. Classification for dogs affected by 
MMVD.Adapted from Atkins C, Bonagura J, Ettinger 
S, et al. (2019) Guidelines for the diagnosis and 
treatment of canine chronic valvular heart disease.  
 
 Definition  
Stage A Dogs at risk for developing MMVD that 
have no identifiable cardiac structural 
disorder (ie, Cavalier King Charles 
spaniel, dachsunds) 
 
Stage B1 Dogs with MMVD that have never 
developed clinical signs and have no 
radiographic or echocardiographic 
evidence of cardiac remodelling 
 
Stage B2 Dogs with MMVD that have never 
developed clinical signs but have 
radiographic or echocardiographic 
evidence of cardiac remodelling (ie, left-
sided heart enlargement) 
 
Stage C Dogs with MMVD and past or current 
clinical signs of heart failure associated 
with structural heart remodeling (dogs 
presenting heart failure for the first time 
may present severe clinical signs and may 
require hospitalisation) 
 
Stage D Dogs with end-stage MMVD and heart 
failure that is refractory to standard 
therapy (ie, furosemide, ACE-I, 
pimobendan , spironolactone) 
 
 
Pimobendan is phosphodiesterase inhibitor acts as 
an inodilator. Its calcium sensitizing effects in conjunction 
with phosphodiesterase inhibition, results in reducing 
afterload by dilating the arteries and veins dilatation. In 
addition, it helps in improving cardiac contractility. 
Benazepril is ACE-I, it helps improving left ventricular 
compliances by inhibiting the production of angiotensin II 
and thus inhibiting the renin angiotensin activating 
system. Furosemide is a potent loop diuretics that prevent 
fluid build up by inhibiting reabsorption of sodium and 
chloride at the ascending loop of Henle. Several 
researches have shown the efficacy of ACE-I and 
Pimobendan in improving the quality of animals’ life with 
clinical improvement seen in coughing, exercise load, 
CHF signs, and as well as survivability. One study even 
demonstrated that Pimobendan statistically brings more 
significant clinical as well as echocardiography 
measurements improvements in dogs with atrioventricular 
disease compared to ACE-I by improving the fractional 
shortening, left atrium to aortic ratio and smaller end 
diastolic volume (Lombard  et al., 2006). Similarly was 
observed in this patients as the clinical sign of coughing 
did not persist or reoccur during treatment with 
pimobendan. 
Regular follow up visit with cardiologist to monitor 
the cardiac diseases progression is recommended. Regular 
blood check-ups are important to monitor the kidney 
functions as well as electrolyte balances. Chest 
radiographs are recommended to evaluate on the presence 
of recurrent sign of congestive heart failure. Dogs with 
MMVD generally have a guarded to poor prognosis 
depending on which stage referring to ACVIM staging.  
Pimobendan is not registered for used in Malaysia 
and its’ use is currently off labelled. This drugs has been 
marketed for more than a decade and much studies has 
been conducted to ensure its benefit in dogs diagnosed 
with MMVD. This medication is beneficial in many ways 
and hence, allowing its’ availibilty for use as treatment of 
cardiomyopathy in dogs escpecially in MMVD is crucial. 
 
CONCLUSION 
 
MMVD is a common cardiac disease in geriatric 
small breed dogs, this disease can progresses into 
refractory heart failure and sudden death is one of the 
consequences of this disease. The treatment for MMVD 
dogs is life long, requires owner’s compliances and it 
should be tailored according to the need of the animal.  
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